Quest Diagnostics will offer the Target Selector lung cancer mutation detection test in that country through a reference agreement with Biocept.
Progenetics will market and distribute Biocept's complete portfolio of Target Selector liquid biopsy assays in Israel. Other terms of the agreement were not disclosed.
The firm saw its Q4 revenues rise to $218,000 year over year, mainly due to expansion of its commercial liquid biopsy testing business.
Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Upon entering the agreement, Aspire purchased $1 million in common stock, and may purchase up to $14 million more at Biocept's discretion.
The partners will use Biocept's liquid biopsy systems to detect estrogen receptor gene mutations that could help guide treatment for women with breast cancer.
Under the agreements, members of Fortified Provider Network and Three Rivers Provider Network will now have access to Biocept's liquid biopsy tests.
It accessioned 482 commercial cases during the quarter, nearly five times the 96 commercial cases for the third quarter of 2014.
Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.
The agreements with the PPOs bring the total number of Americans with covered access to Biocept's tests to about 31 million.
A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.
A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.
Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.
In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.